Guidelines

From the *Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX; †Department of Pediatrics, University of Alberta, Edmonton, AB, Canada; ‡ECLS Program, Toronto General Hospital, Interdepartmental Division of Critical Care Medicine, University of Toronto, Toronto, Canada; §Department of Adult Intensive Care Medicine, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland; ¶Department of Anesthesia, Perioperative, and Pain Medicine, Texas Children's Hospital, Baylor College of Medicine, Houston, TX; and ∥Department of Critical Care Medicine, The Hospital for Sick Children, Toronto, ON, Canada. Reviewers from **Department of Cardiac, Thoracic and Vascular Surgery, National University Hospital Singapore; ††Department of Surgery and Pediatrics, University of Florida, Gainesville, Florida; ‡‡Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota; §§Department of Cardiology, Boston Children's Hospital, Boston, Massachusetts.

Submitted for consideration November 2021; accepted for publication in revised form November 2021.

Disclosure: The authors have no conflicts of interest to report.

Correspondence: Ali B.V. McMichael, Department of Pediatrics, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75235. Email: ali.mcmichael@utsouthwestern.edu.

Copyright © ELSO 2022

DOI: 10.1097/MAT.00000000000001652

Key Words: anticoagulation, extracorporeal membrane oxygenation, extracorporeal life support, unfractionated heparin, direct thrombin inhibitors, activated clotting time, activated partial thromboplastin time, viscoelastic hemostatic assays, antithrombin, blood transfusion, thrombosis

Anticoagulation is necessary for most pediatric and adult extracorporeal membrane oxygenation (ECMO) patients to prevent circuit clotting. Inherently, the most common side effect of anticoagulation is bleeding. Anticoagulation during ECMO is complex due to patient critical illness, interactions between the patient and ECMO circuit, and the inflammatory responses of the patient to illness and to the ECMO circuit which all lead to imbalance in normal patient hemostasis.1

Anticoagulants

Unfractionated heparin (UFH) is currently the most commonly used anticoagulant for pediatric and adult ECMO.2,3 Unfractionated heparin is a glycosaminoglycan that binds to antithrombin (AT) to produce a 1,000-fold increase in AT inhibition. It is metabolized mainly in the liver and primarily excreted in the feces.4

In healthy adults the half-life of UFH is 1 to 2 hours compared with 35 minutes in neonates.7 Although it is rare, UFH can cause heparin induced thrombocytopenia (HIT) in 0.2% to 5% of adult patients.8 Heparin induced thrombocytopenia is more common in adults than pediatrics and is a potentially life-threatening immune-mediated prothrombotic disorder, especially in patients exposed multiple times to heparin.9,10

Alternative anticoagulants, such as direct thrombin inhibitors (DTIs), are being increasingly used off-label for both pediatric and adult ECMO patients. Direct thrombin inhibitors are short-acting anticoagulants that directly inhibit thrombin. Theoretically, DTIs should have a more predictable dosing regimen because, unlike UFH, they bind directly to thrombin without the need for AT and do not bind to other plasma proteins. The two DTIs most commonly used in ECMO are bivalirudin and argatroban. Bivalirudin binds to both circulating and clot-bound thrombin compared with UFH that only binds to freely circulating thrombin. Bivalirudin is primarily metabolized by proteolytic enzymes and 20% is renally excreted. Argatroban is a univalent DTI that reversibly binds and inhibits the active site of thrombin. It is metabolized mainly in the liver and primarily excreted in the feces.

Disadvantages of DTIs include the limited availability of specific laboratory monitoring, lack of specific antidote, higher cost, and limited ECMO experience. While no antidote exists...
Argatroban reversibly binds to thrombin. It is also common for low flow areas in the localized bivalirudin proteolysis and formation of an intracar-diac thrombus. Nonetheless, caution should be used with bivalirudin in low flow states such as severe cardiac dysfunction due to risk of AT, antithrombin; ECMO, extracorporeal membrane oxygenation; UFH, unfractionated heparin.

for DTIs, discontinuation of the agent is often the only treat-Table 1. Summary of the Mechanism of Action, Advantages and Disadvantages of Anticoagulants During ECMO

<table>
<thead>
<tr>
<th>Anticoagulant</th>
<th>Mechanism of Action</th>
<th>Half-Life (mins)</th>
<th>Advantages</th>
<th>Disadvantages</th>
</tr>
</thead>
<tbody>
<tr>
<td>UFH</td>
<td>Main: binds to AT to inhibit thrombin and Xa</td>
<td>60–90 (adults) and 35–75 (pediatrics)</td>
<td>Inexpensive; has antidote (protamine)</td>
<td>Binds to other plasma proteins; heparin induced thrombocytopenia</td>
</tr>
<tr>
<td>Bivalirudin</td>
<td>Reversibly binds to thrombin</td>
<td>25 (adults) and 15–42 (pediatrics)</td>
<td>Does not require AT</td>
<td>No antidote, caution with blood stasis and renal dysfunction</td>
</tr>
<tr>
<td>Argatroban</td>
<td>Reversibly binds to thrombin</td>
<td>39–51</td>
<td>Does not require AT; not degraded by serine proteases</td>
<td>No antidote; variable dosing; caution with hepatic dysfunction</td>
</tr>
</tbody>
</table>

Therapeutic Monitoring of Anticoagulants

The optimal method to measure UFH and DTI efficacy on ECMO is unknown. Anticoagulation monitoring for drug specific effect is done in vitro. As such, this does not take into account endothelial responses nor blood/artificial-surface responses to anticoagulation in vivo during ECMO. This is a major limitation in understanding how coagulation occurs in the patient. The majority of coagulation tests used to monitor anticoagulation are plasma-based tests. Plasma-based tests such as activated partial thromboplastin time (aPTT) are partial functional measures of coagulation and do not account for platelet function or clot strength. In contrast, some whole blood tests such as viscoelastic tests incorporate platelet function and assess clot strength but are not always routinely performed or available at ECMO institutions. Viscoelastic tests also require expertise in viscoelastic technology to interpret and guide clinical management.

A tailored strategy for each patient which allows for interpreta-tion of their anticoagulation monitoring in the context of their individual baseline (as opposed to laboratory baseline), overall inflammatory state (such as septic shock), end-organ dysfunction (liver and kidney) and platelet function as well as consideration of their unique bleeding and clotting risks is needed for optimal anticoagulation. Anticoagulation monitoring tests are only tests: they do not represent in vivo physiology. The clinician must interpret results in the context of their patient and circuit. It is recommended especially in pediatrics or challenging cases to perform both a plasma-based test to measure specific anticoagulant effect and a whole blood test to measure point of care hemostasis.

Table 2 summarizes the advantages and disadvantages of different monitoring techniques for UFH and DTIs and Table 3 describes a suggested anticoagulation monitoring regimen based on ELSO’s recommendations.

Activated Clotting Time

Based on experience with cardiopulmonary bypass and availability as a point of care test, activated clotting time (ACT) was the historical test to monitor ECMO anticoagulation. However, as our understanding of the complexities of anticoagulation and ECMO coagulopathy have evolved, anticoagulation monitoring has intensified in select cases and ACT has been slowly replaced in some centers with other laboratory testing. Activated clotting time measures the time in seconds of whole blood to form fibrin clot after the addition of various coagulation activators. Hence, it does not represent solely UFH effect, but rather provides a physical examination of the blood at the specific time the test is done. Activated clotting time does not measure clot strength. Activated clotting time results will vary based on many factors including platelet number and function, fibrinogen level, coagulation factor deficiencies, temperature, hemodilution, as well as technical factors. Different ACT machines yield different results either because of different coagulation activators or because they are measuring different end points and as a result they cannot be used interchangeably. Activated clotting time is not licensed to monitor DTIs, although it can be used to follow the anticoagulation trends once DTIs are established. Expertise in understanding and interpreting ACT results, rather than adhering to a specific number or range, can make it a useful whole blood test if viscoelastic testing is not routinely available.

Activated Partial Thromboplastin Time

Historically, dose monitoring of patients receiving UFH has been done with aPTT. Activated partial thromboplastin time is also the standard monitoring test for DTIs because of its wide availability. The aPTT test is a plasma-based test that measures the time from factor XII activation to fibrin formation, after calcium is added to the plasma, which was exposed to phospholipid and a contact activator. A prospective, non-ECMO, adult study from 1972 demonstrated that an aPTT between 1.5 and 2.5 times normal was associated with a decreased risk of recurrent venous thromboembolism. Based on this adult study, the therapeutic range for the aPTT was set at 1.5 to 2.5 times the patient’s pretherapy baseline aPTT. However, this was never validated in randomized controlled trials or in ECMO patients. Additionally, in children the baseline aPTT varies with age because of developmental hemostasis.

The use of aPTT for UFH monitoring is based on the assump-tion that the patient’s baseline aPTT is comparable to normal controls and that there is a linear relationship between UFH dose and aPTT. The baseline aPTT in critically ill patients is often different from normal controls which limits the utility of
Table 2. Summary of the Advantages and Disadvantages of Anticoagulation Testing

<table>
<thead>
<tr>
<th>Test</th>
<th>Advantages</th>
<th>Disadvantages</th>
<th>Use in DTI</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACT</td>
<td>Whole blood test. Point of care test. Primary method to monitor UFH in ECMO</td>
<td>Affected by clinical factors including: Thrombocytopenia or platelet dysfunction Elevated d-dimers</td>
<td>Not approved for DTIs</td>
</tr>
<tr>
<td></td>
<td>Widely available. Inexpensive. Examine blood response to all factors influencing hemostasis</td>
<td>Low fibrinogen or other coagulation factor deficiencies. Hypothermia (shortened with hyperthermia). Hemodilution or anemia. Technical factors. Measures end point of the clotting cascade, but does not solely represent UFH effect</td>
<td></td>
</tr>
<tr>
<td>aPTT</td>
<td>Gold standard assay for UFH monitoring outside of ECMO</td>
<td>Plasma test. No standardization between different ACT devices</td>
<td>Yes, standard test for DTI. Underestimates true anticoagulant effect at higher concentration of DTI</td>
</tr>
<tr>
<td></td>
<td>Widely available. Point of care now available</td>
<td>High degree of intrapatient and interpatient variability especially in infants Less reliable in critical illness</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Influenced by blood collection techniques (composition of sampling tube, timing of sample collection)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>No standardization between different aPTT reagents. Requires revalidation of aPTT target range with new lot of reagent</td>
<td></td>
</tr>
<tr>
<td>Anti-Xa Assay</td>
<td>Specific measure of UFH effect based on the ability of UFH to catalyze AT’s inhibition of Factor Xa. Reports of better association with UFH dose and less variability than aPTT</td>
<td>Plasma test. No standardization between assays. Use of exogenous antithrombin or dextran sulphate. Chromogenic assay.</td>
<td>No</td>
</tr>
<tr>
<td>TEG/ROTEM</td>
<td>Whole blood test. Point of care. Provides information about both clot strength and fibrinolysis</td>
<td>Limited availability. Expensive and still considered research for some centers Differences between TEG and ROTEM. Limited data describing correlation with conventional UFH and clinical outcomes</td>
<td>Yes, limited data.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Research assay (unavailable at most centers).</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Not approved by FDA for monitoring of bivalirudin (but approved for dabigatran and argatroban).</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Limited availability. Research only.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Thrombin time. Linear response to DTI concentration. Unaffected by variations in clotting factors including fibrinogen.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Thrombin time. Linear response to DTI concentration. Unaffected by variations in clotting factors including fibrinogen.</td>
<td></td>
</tr>
</tbody>
</table>

ACT, activated clotting time; aPTT, activated partial thromboplastin time; AT, antithrombin; DTI, dilute thrombin time; ECMO, extracorporeal membrane oxygenation; FDA, food and drug administration; TEG, thromboelastography; UFH, unfractionated heparin; UFH, unfractionated heparin.

As a result, aPTT demonstrates a high degree of intrapatient and interpatient variability that can result in an increased number of aPTT tests drawn for UFH monitoring and frequent UFH dose changes. Consequently, many clinical laboratories and clinicians have substituted the anti-Xa assay for UFH monitoring.

**Anti-Xa Assay**

The anti-Xa assay is a measure of UFH effect based on the ability of UFH to catalyze AT’s inhibition of factor Xa activity. Anti-Xa is not used for DTIs. Anti-Xa is a plasma-based test that evaluates only one chemical reaction of the UFH-AT complex and thus does not measure inhibition of thrombin nor does it incorporate platelet function. However, anti-Xa is used as a surrogate measure of the overall anticoagulant activity of UFH. An adult randomized controlled trial (RCT) of patients with acute venous thromboembolism reported that an anti-Xa of 0.35 to 0.67 U/ml and a PTT of 60 to 85 seconds were equivalent to a heparin level of 0.2 to 0.4 U/ml by a protamine titration. These important to note that anti-Xa assays vary amongst institutions as to whether exogenous AT is added to the assay or if dextran sulphate is present in the reagent. Calibrators will also vary across institutions. Because it is a colorimetric assay, pigmented

Adapted from Brogan.30

- If patient is clinically stable with no bleeding or clotting, it is reasonable to draw complete blood count and coagulation labs once daily.

ACT, activated clotting time; aPTT, activated partial thromboplastin time; CBC, complete blood count; INR, international normalized ratio.

Table 3. Suggested Anticoagulation Monitoring Laboratory Schedule*

<table>
<thead>
<tr>
<th>Laboratory Test</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACT</td>
<td>Q1h–Q2h</td>
</tr>
<tr>
<td>aPTT</td>
<td>Q6h–Q12h</td>
</tr>
<tr>
<td>Anti-factor Xa assay</td>
<td>Q6h–Q12h</td>
</tr>
<tr>
<td>Platelets</td>
<td>Q6h–Q12h</td>
</tr>
<tr>
<td>INR</td>
<td>Q12h–Q24h</td>
</tr>
<tr>
<td>Fibrinogen</td>
<td>Q12h–Q24h</td>
</tr>
<tr>
<td>CBC</td>
<td>Q12h–Q24h</td>
</tr>
<tr>
<td>Antithrombin level</td>
<td>Daily–PRN</td>
</tr>
<tr>
<td>Thromboelastography</td>
<td>Daily–PRN</td>
</tr>
<tr>
<td>Plasma free hemoglobin</td>
<td>Daily–PRN</td>
</tr>
<tr>
<td>Thromboelastometry</td>
<td>Daily–PRN</td>
</tr>
</tbody>
</table>

*If patient is clinically stable with no bleeding or clotting, it is reasonable to draw complete blood count and coagulation labs once daily.

ACT, activated clotting time; aPTT, activated partial thromboplastin time; CBC, complete blood count; INR, international normalized ratio.
The viscoelastic hemostatic assays (VHA) are whole blood point of care coagulation assays used to measure the viscoelastic properties of the clot (Figure 1). Compared with standard coagulation tests including aPTT, anti-Xa, and ACT, VHAs allow for a global assessment of clot initiation (e.g., clotting time), clot strength or amplitude (e.g., fibrinogen and platelet contribution), and clot stability (e.g., fibrinolysis). The platelet contribution to clot formation can be calculated by the difference between the amplitudes measured after extrinsic or intrinsic activation and fibrinogen assays. While several devices were developed over the past decade, only two have been validated for clinical use: thromboelastometry (ROTEM) and thromboelastography (TEG). Each device comes with multiple assays allowing for extrinsic or intrinsic activation and fibrinogen assays. While several devices were developed over the past decade, only two have been validated for clinical use: thromboelastometry (ROTEM) and thromboelastography (TEG). Each device comes with multiple assays allowing for a global assessment of clot initiation (e.g., clotting time), clot strength or amplitude (e.g., fibrinogen and platelet contribution), and clot stability (e.g., fibrinolysis). The platelet contribution to clot formation can be calculated by the difference between the amplitudes measured after extrinsic or intrinsic activation and fibrinogen assays. While several devices were developed over the past decade, only two have been validated for clinical use: thromboelastometry (ROTEM) and thromboelastography (TEG). Each device comes with multiple assays allowing for extrinsic (EXTEM on ROTEM, RapidTEG on TEG) and intrinsic (INTEM on ROTEM and Kaolin-activated TEG) clot activation, assessment of fibrinogen contribution to formation (FIBTEM on ROTEM and FF-TEG), as well as heparinase assays (HEPTEM on ROTEM and Heparinase Kaolin-TEG).

### Table 4. ELSO Suggested UFH Titration and ACT Goal Range Based on Anti-Factor Xa Levels

<table>
<thead>
<tr>
<th>Anti-Factor Xa Goal Level (units/ml)</th>
<th>Anti-Factor Xa Range (units/ml)</th>
<th>UFH Rate Change</th>
<th>ACT Goal Range (s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.3–0.5</td>
<td>&lt;0.3</td>
<td>↑10%–20%</td>
<td>↑110–200</td>
</tr>
<tr>
<td></td>
<td>0.3–0.5</td>
<td>No change</td>
<td>No change</td>
</tr>
<tr>
<td></td>
<td>&gt;0.5</td>
<td>↑10%–20%</td>
<td>↑110–200</td>
</tr>
<tr>
<td>0.4–0.6</td>
<td>&lt;0.4</td>
<td>↑10%–20%</td>
<td>↑110–200</td>
</tr>
<tr>
<td></td>
<td>0.4–0.6</td>
<td>No change</td>
<td>No change</td>
</tr>
<tr>
<td></td>
<td>&gt;0.6</td>
<td>↑10%–20%</td>
<td>↑110–200</td>
</tr>
<tr>
<td>0.5–0.7</td>
<td>&lt;0.5</td>
<td>↑10%–20%</td>
<td>↑110–200</td>
</tr>
<tr>
<td></td>
<td>0.5–0.7</td>
<td>No change</td>
<td>No change</td>
</tr>
<tr>
<td></td>
<td>&gt;0.7</td>
<td>↑10%–20%</td>
<td>↑110–200</td>
</tr>
</tbody>
</table>

Adapted from Brogan.30

ACT, activated clotting time; UFH, unfractionated heparin.

or opaque plasma, such as that due to high bilirubin, triglyceride or free hemoglobin levels can result in an underestimation of UFH effect.34 Table 4 outlines ELSO’s suggested UFH titration based on anti-Xa levels. In addition, Table 5 describes factors to consider when aPTT and anti-Xa testing are discordant.

### Table 5. Algorithm for Discrepant Anticoagulation Tests

<table>
<thead>
<tr>
<th>Anti-Factor Xa (0.3–0.7 IU/ml)</th>
<th>aPTT (60–90s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Normal</td>
<td>Normal</td>
</tr>
<tr>
<td>High</td>
<td>High</td>
</tr>
</tbody>
</table>

Increase heparin

Low: Consider hypercoagulable state; unlikely to occur; consider repeating labs

Normal: No change; consider repeating labs

High: Consider factor deficiency and repletion with FFP; repeat aPTT, consider FFP if still high

aPTT, activated partial thromboplastin time; FFP, fresh frozen plasma.

viscoelastic hemostatic assays have been used in several randomized controlled trials in patients undergoing cardiac surgery.16,19 The literature regarding use of VHAs in ECMO is increasing and small RCTs and retrospective case series have shown differing results regarding use of VHAs as predictors of clotting and bleeding.50–51

**Antithrombin**

Monitoring of AT has a strong pharmacologic rationale when using UFH, however, there is not consistent data suggesting that monitoring or replacing AT improves outcomes. Previous retrospective studies described that anticoagulation targets may be reached more easily, although not significantly, and lower doses of UFH may be required when AT supplementation is used.44,45 A highly anticipated pilot RCT of adult VV-ECMO patients randomizing patients to receive AT to achieve a goal 80% to 120% versus control found no difference in total UFH dose, bleeding, transfusion need, or thrombosis. However, a posthoc analysis reported that patients who received AT and had an AT level <60% had a decrease in UFH dose.46 More evidence is needed before recommending routine AT monitoring and supplementation.

**Future Tests for Direct Thrombin Inhibitors**

Activated partial thromboplastin time is currently the standard test for monitoring DTIs, but at higher doses of DTIs, such as those used for cardiopulmonary bypass in patients with HIT, aPTT shows a nonlinear response to DTI dose.47 Plasma dilute thrombin time and ecarin chromogenic assay may be superior tests, but they are not available at most institutions.48,49 When using DTIs, it is strongly suggested to have clinicians with expertise both in anticoagulation and ECMO to aid in dosing, monitoring, clinical management, and complications.

In summary, each anticoagulation monitoring test has merits and disadvantages. For each center an approach that allows for a tailored regimen of anticoagulation (regardless of agent used) and monitoring is necessary. At the very least, both a plasma-based test for anticoagulant effect and whole blood POC test for hemostasis should be available.

**Recommendations Specific to Adult ECMO Patients**

There is variability in anticoagulation practices for adults supported with ECMO and as in pediatric ECMO this remains an area of active investigation. Importantly, some issues related...
to developmental hemostasis or to the use of lower blood flows associated with pediatric ECMO are less of a concern in adults, making typical anticoagulation strategies easier. Nevertheless, the rate of bleeding and thrombotic complications is still a concern and is the motivation for the development of new strategies.

There is currently a paucity of evidence to guide optimal anticoagulation management in adult ECMO patients. The current tendency is towards less anticoagulation especially in VV-ECMO where multiple retrospective studies suggest that either lower (or no) anticoagulation is safe and feasible. Although these data are encouraging, we cannot yet recommend the routine use of no anticoagulation for VV-ECMO. The most recent pilot randomized study of low heparin versus usual care showed a significant decrease in the dose of heparin and in the mean aPTT and anti-Xa without increasing the rate of complications. However, this study did not conclude on the superiority of a low-dose heparin protocol for ECMO. Fortunately, there are both ongoing (NCT04496362) and planned (NCT04273607) studies that will help to answer the question regarding the safety of a no anticoagulation strategy for adult VV-ECMO.

For VA-ECMO, given the concerns of systemic emboli, the routine use of anticoagulation is currently recommended. A recent retrospective study on VA-ECMO patients suggested that the absence of anticoagulation is safe in adult VA-ECMO patients and is associated with decreased transfusion and hemorrhagic complication without an increase in thrombotic events. However, well-powered randomized controlled trials are still needed to draw definitive conclusions on the safety and feasibility of VA-ECMO without anticoagulation.

Management of Bleeding and Thrombotic Complications

Optimal Blood Product Replacement

There is a lack of studies to guide blood product transfusion practices in ECMO patients. Table 6 describes one approach for blood product replacement based on clinical experience and local center clinical guidelines.
INR <1.5 (bleeding patient) Fresh frozen plasma 10 ml/kg (max 2 units)
Fibrinogen >1.5 g/L (bleeding patient or before surgical intervention) Cryoprecipitate 1 unit/5 kg (max 6 units)
Hemoglobin >70–90 g/L (consider higher goal for neonates and children with cyanotic congenital heart disease or lower goal for stable, adult patients) Packed RBCs 10 ml/kg (max 2 units)
Antithrombin >50%–80% (>0.5–0.8 U/ml), consider AT replacement if on maximum dose of UFH and unable to obtain anticoagulation goals

AT, antithrombin; RBCs, red blood cells; INR, international normalized ratio; UFH, unfractionated heparin.

A survey of 187 ECMO centers in 2013 by Bembea et al. found variable thresholds for blood product transfusion with the majority of centers using a hematocrit of 35% with a range of 25% to 40% as a trigger for transfusion of red blood cells. The current ELSO Red Book recommends maintaining a hemoglobin of 140 to 150 g/L or hematocrit >40. The median platelet count that triggered platelet transfusion in the survey was 100,000 × 10⁹/L with a range of 50,000 to 200,000 × 10⁹/L. The survey was repeated in 2021 and found that platelet transfusion practices still vary widely amongst pediatric ECMO centers. Given concerns about the association of fluid overload and mortality as well as blood product storage issues, some centers are reexamining their transfusion thresholds and suggest that a conservative transfusion strategy may be safe in the adult ECMO population. Unfortunately, insufficient evidence currently exists to define a safe lower hemoglobin threshold for children. Given this lack of evidence, recent expert consensus guidelines for pediatric ECMO patients recommended focusing on markers of adequate regional and systemic oxygen delivery such as mixed venous saturation, lactate, systemic oxygen saturation, and cerebral and somatic oximetry in addition to the hemoglobin number.

For adults, the most recent survey on anticoagulation practice demonstrated that more than 75% of the centers (N = 47) used a hemoglobin threshold of 100 g/L and 45% of the centers used 80 g/L as a transfusion threshold. The most common platelet threshold was 50,000 × 10⁹/L in 67% of the centers and most common fibrinogen transfusion threshold was 2 g/L. More recently, a Canadian expert consensus document for the adult VV nonbleeding ECMO patient recommended a transfusion threshold of 70 to 75 g/L for hemoglobin and 50,000 × 10⁹/L for platelets. Although there is a lack of studies, a restrictive strategy seems reasonable in nonbleeding adult ECMO patients.

### Hemorrhage and Thrombosis

Both bleeding and thrombotic complications are associated with increased morbidity and mortality. Overall, bleeding complications are more frequent than thrombotic complications. If there is excessive bleeding, particularly in postcardiectomy patients, holding the UFH for 4 to 6 hours is reasonable. In some circumstances where bleeding is difficult to control, the UFH may be held up to 12 hours or longer until bleeding is controlled. Case reports in trauma patients with a high risk of bleeding have shown feasibility in running heparin-free ECMO circuits. If anticoagulation is held, frequent evaluation of the need to restart anticoagulation and the circuit thrombus burden is recommended as thrombosis of the circuit could result in catastrophic complications or death.

Surgical site bleeding may be controlled locally by topical hemostats such as gauze swabs, gelatin sponge (Gelfoam), thrombin soaked gelfoam, thrombin bonded gelatin granules (Flo-Seal), oxidized cellulose (Surgicel), or thrombin and fibrinogen sealant (Tisseel). For clinically significant bleeding or following major procedures on ECMO, aminocaproic acid (Amicar) and tranexamic acid (TXA) have been shown in some studies to reduce incidence of surgical bleeding when used prophylactically or after surgical operation while others have shown no difference in bleeding outcomes. Both these agents function through the inhibition of plasminogen conversion and thus prevent fibrinolysis. In addition, they optimize platelet functionality. Nonspecific risk of thrombosis is likely increased when antifibrinolytics are administered. Monitoring response with VHA is suggested, if available.

Circuit thrombosis becomes clinically relevant if it requires circuit intervention or is associated with severe hemolysis. Hemolysis is an under-recognized complication as not all ECMO centers measure plasma free hemoglobin. Hemolysis occurs when the red blood cell membrane ruptures because of mechanical trauma, releasing free hemoglobin into the plasma. The circulating free hemoglobin precipitates in renal tubules, which may lead to hemoglobinuria nephropathy. Free hemoglobin in plasma is also cytotoxic leading to endothelial dysfunction and vasoconstriction secondary to the consumption of nitric oxide. The free hemoglobin concentration in ECMO patients is associated with risks of both renal impairment and death. When plasma free hemoglobin is not readily available, other measures routinely performed such as d-dimer, transmembrane pressure, and platelet count can also be used as surrogate markers for potential increase in circuit thrombotic load. In small retrospective studies, increase in d-dimer in particular has been shown to be an early predictor of membrane oxygenator failure.

In conclusion, the current data and practices developed through decades of experience suggest that anticoagulation should be used for most ECMO patients, although there are some clear differences between children and adults. Thrombosis and hemorrhagic management during ECMO should be tailored to the individual patient and condition being supported by ECMO. New developments in circuit materials and an increasing experience in the management of ECMO in large centers may allow for
more restrictive anticoagulation strategies to be developed. We recommend each center develop a local strategy for anticoagulation based on experience as well as availability of different monitoring techniques. Consultation with a hematologist or ECMO experts specializing in anticoagulation should be considered for managing complex hemorrhagic or thrombotic complications or other difficulties in anticoagulation. Multicenter research is vital to uniformize practices and improve patient outcomes.

Acknowledgment

We thank Elaine Cooley, MSN RN, Peter Rycus, MPH, Christine Stead, CEO, and the ELSO Board Members for their invaluable contribution to the development of this guideline.

References


